SYNCOMF - Syncom Formul.
📢 Recent Corporate Announcements
Syncom Formulations (India) Limited reported a strong bottom-line performance for Q3 FY26, with net profit rising 47.4% YoY to ₹18.86 crore. This growth comes despite a 9.8% YoY decline in revenue from operations, which stood at ₹114.59 crore. The profitability surge was largely due to a sharp 37.8% reduction in raw material costs, significantly improving operating margins. Additionally, the company is facing a legal challenge regarding a ₹5.44 crore GST demand, which it plans to appeal.
- Standalone Net Profit increased 47.4% YoY to ₹18.86 crore from ₹12.79 crore.
- Revenue from operations declined 9.8% YoY to ₹114.59 crore compared to ₹127.03 crore.
- Raw material costs decreased significantly to ₹47.45 crore from ₹76.26 crore YoY, driving margin expansion.
- Basic and Diluted EPS improved to ₹0.23 from ₹0.14 in the corresponding quarter last year.
- Company disclosed a legal contest against a ₹5.44 crore GST demand involving ineligible Input Tax Credit.
Syncom Formulations (India) Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the period ended December 31, 2025. The company's Registrar and Share Transfer Agent, Ankit Consultancy Pvt. Ltd., confirmed that all dematerialization requests were processed and confirmed to depositories. The physical security certificates received were mutilated and cancelled after due verification. This routine filing ensures that the company's share records are accurately maintained between the registrar and the depositories (NSDL and CDSL).
- Compliance certificate issued for the quarter ended December 31, 2025.
- Registrar confirmed dematerialization requests were processed within the mandatory 15-day window.
- Physical certificates were cancelled and substituted with the names of depositories in the register of members.
- Confirmation provided that dematerialized securities are listed on the BSE and NSE stock exchanges.
Syncom Formulations (India) Limited has received a revised demand notice from the GST department totaling ₹1,41,78,604. The demand consists of ₹70,89,302 for ineligible Input Tax Credit (ITC) and an equivalent penalty of ₹70,89,302 under the CGST Act. This follows the rejection of the company's previous appeal against a demand originally raised in April 2025. The company intends to further contest this demand by filing an appeal with the relevant appellate authority.
- Total financial impact of ₹1.42 crore including tax demand and 100% penalty
- Demand pertains to alleged ineligible input services and blocked credits under Section 74(5) and 122 of CGST Act
- The revised notice was received on January 2, 2026, following a rejected appeal
- The department has set a payment deadline of January 31, 2026
- Company plans to move for a further appeal to contest the demand
Syncom Formulations (India) Limited has announced that its trading window will be closed starting January 1, 2026, for all designated persons and their relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations ahead of the Q3 FY26 financial results. The window will remain shut until 48 hours after the declaration of the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The company has coordinated with CDSL to freeze the PANs of designated persons during this period to prevent any insider trading.
- Trading window closure commences on January 1, 2026, for the Q3 FY26 reporting period.
- Restriction applies to all Promoters, Directors, KMPs, and designated employees.
- The window will reopen 48 hours after the announcement of financial results for the quarter ended December 31, 2025.
- CDSL will implement PAN-level freezing for designated persons as per SEBI's framework.
- The specific date for the Board Meeting to approve the results will be announced separately.
Financial Performance
Revenue Growth by Segment
Pharmaceuticals Drugs & Formulations revenue grew 30.5% YoY to INR 246.98 Cr in H1 FY26. Trading of Commodities revenue fell 72.7% to INR 1.05 Cr. Renting of Property revenue decreased 3% to INR 1.88 Cr.
Profitability Margins
Net Profit Margin (based on Total Comprehensive Income) improved to 14.5% in H1 FY26 from 13.0% in H1 FY25. Profit Before Tax (PBT) margin increased significantly to 16.9% from 12.8% YoY.
EBITDA Margin
EBITDA margin is approximately 18.2% for H1 FY26 (INR 45.50 Cr EBITDA on INR 249.90 Cr revenue), up from approximately 15.8% in H1 FY25.
Capital Expenditure
Not explicitly disclosed, but the company accepted a material bid for a commercial property from HDFC Bank in November 2025, indicating significant upcoming investment in fixed assets.
Credit Rating & Borrowing
Borrowing costs are minimal, with finance costs of INR 0.52 Cr in H1 FY26, representing only 0.2% of total revenue.
Operational Drivers
Raw Materials
Active Pharmaceutical Ingredients (APIs) and excipients; specific percentage of total cost not disclosed.
Capacity Expansion
Infrastructure expansion is planned via the acquisition of a material commercial property from HDFC Bank accepted on November 22, 2025.
Raw Material Costs
Not disclosed as a specific percentage of revenue, but the company saw an inventory reduction of INR 12.82 Cr, suggesting efficient use of existing stock.
Strategic Growth
Expected Growth Rate
28%
Growth Strategy
The company is focusing on its core Pharmaceutical segment, which saw 30.5% YoY growth. The acquisition of a material commercial property from HDFC Bank in Nov 2025 suggests expansion of administrative or operational footprint to support this growth. Cost optimization is evident as segment profits grew faster (73.6%) than revenue (30.5%).
Products & Services
Pharmaceutical drugs and formulations (medicines).
Strategic Alliances
The company operates through three wholly-owned subsidiaries: Synmex Pharma Pvt. Ltd., Sante Biotech Pvt. Ltd., and Vincit Biotech International Pvt. Ltd.
External Factors
Industry Trends
The Indian pharmaceutical industry is growing at 10-12% CAGR, but Syncom is outperforming at 30.5% YoY. The industry is moving towards stricter compliance and digital manufacturing.
Competitive Landscape
Operates in the highly competitive Indian generic pharmaceutical market with numerous domestic players.
Competitive Moat
Syncom's moat lies in its integrated manufacturing setup in Pithampur and its ability to scale the Pharma segment profitably (margins improved from 12.5% to 16.6% YoY). This cost leadership is a durable advantage in the generic drug market.
Macro Economic Sensitivity
Low sensitivity to interest rates due to minimal finance costs (0.2% of revenue).
Consumer Behavior
Increasing demand for affordable healthcare and generic formulations.
Regulatory & Governance
Industry Regulations
Pharmaceutical manufacturing is subject to GMP (Good Manufacturing Practices) and pricing controls under the Drug Price Control Order (DPCO).
Taxation Policy Impact
Effective tax rate is approximately 14% based on H1 FY26 results.
Risk Analysis
Key Uncertainties
Concentration risk in the pharma segment (98.8% of revenue); any regulatory crackdown on manufacturing sites (Pithampur) could halt nearly all revenue.
Credit & Counterparty Risk
Receivables quality appears high as trade receivables decreased by INR 5.31 Cr during H1 FY26, indicating effective cash collection.